First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor

Neoplasm Malignant Clinical Trial

Official title:

Dose Escalation, Safety and Pharmacokinetic, First in Man Study, of SAR566658 Administered as a Single Agent by Intravenous Infusion in Adult Patients With CA6-Positive and Refractory Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01156870
• Other study ID #: TED10499
• Secondary ID: U1111-1116-4129
• Status: Completed
• Phase: Phase 1
• First received: July 2, 2010
• Last updated: May 9, 2017
• Start date: September 8, 2010
• Est. completion date: April 7, 2017

Study information

• Verified date: May 2017
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Primary Objective:

To determine the maximum tolerated dose (MTD) of SAR566658

Secondary Objectives:

• To characterize the safety profile of SAR566658

• To evaluate the pharmacokinetic profile of SAR566658

• To assess the potential immunogenicity of SAR566658

• To assess preliminary antitumor activity

• To assess the effect of SAR566658 at recommended dose on CYP3A enzyme activity using midazolam

• To assess safety in the alternative schedules of SAR566658 administration

Description:

The duration of the study for one patient in the dose escalation phase of the study will include a screening period of up to 3 weeks, a 3-week treatment cycle(s) and a 2-week treatment cycle(s). The patients may continue treatment until disease progression, unacceptable toxicity, or willingness to stop, followed by a minimum of 30-day follow-up. If a patient treated in dose escalation part or in an expansion cohorts, continues to benefit from the treatment at the time of Clinical Study Report, the patient can continue study treatment and will continue to undergo all assessments as per the study flowchart. Such patients will be followed at least until 30 days after the last IMP administration.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 114
• Est. completion date: April 7, 2017
• Est. primary completion date: April 7, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

Diagnosis of CA6-positive solid tumors as moderate to intense membrane staining of =15% of tumor cells for which no standard therapy is available.

Exclusion criteria:

• Eastem Cooperative Oncology Group performance status =2.

• Any serious active disease or co-morbid condition, which, in the opinion of the Investigator, may interfere with the safety or the compliance with the study.

• Poor bone marrow reserve.

• Poor liver and renal function.

• Pregnant or breast-feeding woman.

• No use of effective birth control methods, when applicable.

• No resolution of all specific toxicities (excluding alopecia) related to any prior anti-cancer therapy to Grade =1 according to the National Cancer Institute - Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 4.03 grade scaling.

• Wash out period of less than 3 weeks from previous antitumor therapy or any investigational treatment, (and less than 6 weeks in case of prior nitroso-urea and or mitomycin C treatment). Patients will be eligible if hormonotherapy (ie, for breast tumors) is discontinued before first Investigational product administration.

• Wash out period of less than 1 week from last palliative dose of radiotherapy.

• Patients with respiratory insufficiency defined by a decrease more than 50% compared to theoretical baseline pulmonary volumes and theoretical baseline Diffusing capacity of the Lung for Carbon monoxyde.

• Any lung radiotherapy in patient's cancer history.

• Patients with previous history or active interstitial lung disease or pulmonary fibrosis.

• Patients with abnormal cardiac function defined by a Left Ventricular Ejection Fraction <50%.

• Patients with previous history of acute cardiac failure.

• Patients with previous history and/or unresolved corneal disorders.

• Known intolerance to infused protein products or maytansinoids.

• Patients treated with strong CYP3A inhibitors within 2 weeks prior study drug administration.

• For patients to be treated in the midazolam cohort:

• Any treatment known to induce CYP3A isoenzymes or to inhibit CYP3A4 activities not allowed within 2 weeks before midazolam administration and up to the end of pharmacokinetic sampling following the last midazolam administration.

• Any contra-indications to midazolam, according to the applicable labeling.

• Patients older than 60 years.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Related Conditions & MeSH terms

• Neoplasm Malignant
• Neoplasms

Intervention

Drug:
• SAR566658
Pharmaceutical form:solution for infusion Route of administration: intravenous

Locations

Country	Name	City	State
France	Investigational Site Number 250001	Toulouse Cedex
Spain	Investigational Site Number 724001	Madrid
Spain	Investigational Site Number 724002	Madrid
United States	Investigational Site Number 840002	Cincinnati	Ohio
United States	Investigational Site Number 840001	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Countries where clinical trial is conducted

United States,  France,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose Escalation to determine the maximum tolerated dose (MTD) of SAR566658		3 weeks
Primary	Extension Cohorts to evaluate the preliminary anti-tumoral effect of SAR566658		Anticancer activity is assessed every 6 weeks
Primary	To assess the effect of SAR566658 at the recommended dose on CYP3A enzyme activity using midazolam as probe		At D1 and D4 of administration of SAR566658 for 24h of midazolam dosing
Secondary	Overall safety profile based on adverse events reporting, laboratory tests, vital signs and specific pulmonary and ocular tests, according to the NCI-CTC AE v4.03		Up to 2 years
Secondary	Pharmacokinetic (PK) parameters		Up to 2 years
Secondary	Immunogenicity evaluation (anti-drug antibodies)		Up to 2 years
Secondary	Antitumoral response		Up to treatment discontinuation
Secondary	To assess the effect of SAR566658 at recommended dose on CYP3A enzyme activity using midazolam		Up to Cycle 2
Secondary	To assess safety in the alternative schedules of SAR566658 administration		Up to 2 years